Esperion to Report First Quarter 2025 Financial Results on May 6

Rhea-AI Summary

Esperion (NASDAQ: ESPR) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025, before market opening. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.

Esperion is a commercial stage biopharmaceutical company that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial, which included nearly 14,000 patients.

The company is also advancing its next generation program focusing on ATP citrate lyase inhibitors (ACLYi), utilizing new insights into structure and function for rational drug design of highly potent and specific inhibitors with allosteric mechanisms.

Positive

• FDA-approved oral, once-daily, non-statin medicines in commercial stage
• Large-scale clinical validation with 14,000-patient CLEAR trial
• Advancing next-generation ACLYi drug development program

Negative

• None.

ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025.

Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.

A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When will Esperion (ESPR) release Q1 2025 earnings?

Esperion will release Q1 2025 financial results before market opens on Tuesday, May 6, 2025, followed by a webcast at 8:00 a.m. ET.

What is the main product focus of Esperion (ESPR)?

Esperion focuses on FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C.

How many patients were involved in Esperion's CLEAR Cardiovascular Outcomes Trial?

The CLEAR Cardiovascular Outcomes Trial included nearly 14,000 patients.

What is Esperion's next generation drug development program?

Esperion is developing ATP citrate lyase inhibitors (ACLYi) with focus on highly potent and specific inhibitors using allosteric mechanisms.